Anagrelide

Anagrelide
Clinical data
Trade names	Agrylin
AHFS/Drugs.com	Monograph
MedlinePlus	a601020
Pregnancy; category	AU: B3;
Routes of; administration	By mouth
ATC code	L01XX35 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Metabolism	Liver, partially through CYP1A2
Elimination half-life	1.3 hours
Excretion	Urine (<1%)
Identifiers
	IUPAC name 6,7-dichloro-1,5-dihydroimidazo; (2,1-b)quinazolin-2(3H)-one;
CAS Number	68475-42-3 ;
PubChem CID	2182;
IUPHAR/BPS	7114;
DrugBank	DB00261 ;
ChemSpider	2097 ;
UNII	K9X45X0051;
KEGG	D07455 ;
ChEBI	CHEBI:142290 ;
ChEMBL	ChEMBL760 ;
CompTox Dashboard (EPA)	DTXSID4048305 ;
ECHA InfoCard	100.317.113
Chemical and physical data
Formula	C10H7Cl2N3O
Molar mass	256.09 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C1NC2=Nc3c(CN2C1)c(Cl)c(cc3)Cl;
	InChI InChI=1S/C10H7Cl2N3O/c11-6-1-2-7-5(9(6)12)3-15-4-8(16)14-10(15)13-7/h1-2H,3-4H2,(H,13,14,16) ; Key:OTBXOEAOVRKTNQ-UHFFFAOYSA-N ;
	(verify)

Anagrelide (Agrylin/Xagrid, Shire and Thromboreductin, AOP Orphan Pharmaceuticals AG) is a drug used for the treatment of essential thrombocytosis (also known as essential thrombocythemia), or overproduction of blood platelets. It also has been used in the treatment of chronic myeloid leukemia.

Anagrelide controlled release (GALE-401) is in phase III clinical trials by Galena Biopharma for the treatment of essential thrombocytosis.